• 1. Distinct roles of SNARE-mimicking lipopeptides during initial steps of membrane fusion?
  Alena Koukalová,?árka Pokorná,Aimee L. Boyle,Nestor Lopez Mora,Alexander Kros,Martin Hof,Radek ?achl Nanoscale, 2018,10, 19064-19073
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives

Recent Advances in the Study of 8-Ethynylquinoline (CAS: 103987-81-1) in Chemical Biology and Pharmaceutical Research

8-Ethynylquinoline (CAS: 103987-81-1) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a key building block in the synthesis of novel therapeutic agents, particularly in the fields of oncology and infectious diseases. This research brief aims to provide an overview of the latest findings related to 8-Ethynylquinoline, focusing on its chemical properties, biological activities, and potential therapeutic applications.

One of the most notable advancements in the study of 8-Ethynylquinoline is its role as a potent inhibitor of specific enzymatic pathways. Recent research published in the Journal of Medicinal Chemistry demonstrated that 8-Ethynylquinoline exhibits strong inhibitory effects against certain kinases involved in cancer cell proliferation. The study utilized a combination of in vitro assays and molecular docking simulations to elucidate the binding mechanisms of 8-Ethynylquinoline with its target proteins, providing valuable insights for the design of next-generation kinase inhibitors.

In addition to its anticancer properties, 8-Ethynylquinoline has also been investigated for its antimicrobial activity. A 2023 study in Bioorganic & Medicinal Chemistry Letters reported that derivatives of 8-Ethynylquinoline showed promising efficacy against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The researchers attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, suggesting its potential as a scaffold for developing new antibiotics.

The chemical versatility of 8-Ethynylquinoline has further been explored in the context of click chemistry applications. Its ethynyl group makes it an excellent candidate for copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions, which are widely used in bioconjugation and drug delivery systems. Recent work in this area has focused on optimizing the reaction conditions to improve yield and selectivity, paving the way for more efficient synthesis of complex molecular architectures.

From a pharmacological perspective, pharmacokinetic studies of 8-Ethynylquinoline have revealed both challenges and opportunities. While the compound demonstrates favorable absorption and distribution profiles, its metabolic stability in vivo remains an area of active investigation. Current research efforts are directed toward structural modifications that could enhance metabolic stability without compromising biological activity.

Looking ahead, the potential applications of 8-Ethynylquinoline appear promising but require further validation through preclinical and clinical studies. The compound's unique chemical properties and demonstrated biological activities position it as a valuable tool for both basic research and drug development. Future directions may include exploring its use in combination therapies, targeted drug delivery systems, and as a molecular probe for studying biological pathways.

• 610-51-5(Acridine, 4-methyl-)
• 2436-93-3(Quinoline,6,8-dimethyl-)
• 13991-56-5(Benz[a]acridine,8-methyl-)
• 53-69-0(Benz[a]acridine,8,10-dimethyl-)
• 78593-41-6(6-Ethynylquinoline)
• 20668-29-5(Quinoline,3,8-dimethyl-)
• 62365-78-0(3-Ethynylindole)
• 78593-40-5(3-Ethynylquinoline)
• 3295-58-7(Acridine, 4,5-dimethyl-)
• 78593-42-7(4-ethynylisoquinoline)